Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-201 in GPC3-positive Advanced Solid Tumors
NCT06687941Phase 1Recruiting
- Sponsor
- Aptamer Sciences Inc.
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- RNA Aptamers, Small Molecules, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AST-201 in solid tumor, hepatocellular carcinoma (HCC), non-small cell lung carcinoma (NSCLC) and 1 more, sponsored by Aptamer Sciences Inc. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Mar 2025; status: recruiting.
02
Drugs
AST-201
03
Conditions
solid tumorhepatocellular carcinoma (HCC)non-small cell lung carcinoma (NSCLC)liver neoplasms
Beyond the preview
Go deeper on NCT06687941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687941.